Next Article in Journal
Development of a Taste-Masked Orodispersible Film Containing Dimenhydrinate
Previous Article in Journal
Development Strategies for Herbal Products Reducing the Influence of Natural Variance in Dry Mass on Tableting Properties and Tablet Characteristics

Bioavailability of a Lipidic Formulation of Curcumin in Healthy Human Volunteers

Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar, Punjab-160062, India
Auriga Research Limited, Kirti Nagar Industrial Area, New Delhi-110015, India
Author to whom correspondence should be addressed.
Pharmaceutics 2012, 4(4), 517-530;
Received: 15 June 2012 / Revised: 21 August 2012 / Accepted: 27 September 2012 / Published: 9 October 2012
Numerous publications have reported the significant pharmacodynamic activity of Curcumin (CRM) despite low or undetectable levels in plasma. The objective of the present study was to perform a detailed pharmacokinetic evaluation of CRM after the oral administration of a highly bioavailable lipidic formulation of CRM (CRM-LF) in human subjects. Cmax, Tmax and AUC0–¥ were found to be 183.35 ± 37.54 ng/mL, 0.60 ± 0.05 h and 321.12 ± 25.55 ng/mL respectively, at a dose of 750 mg. The plasma profile clearly showed three distinct phases, viz., absorption, distribution and elimination. A close evaluation of the primary pharmacokinetic parameters provided valuable insight into the behavior of the CRM after absorption by CRM-LF. CRM-LF showed a lag time (Tlag) of 0.18 h (around 12 min). Pharmacokinetic modeling revealed that CRM-LF followed a two-compartment model with first order absorption, lag time and first order elimination. A high absorption rate constant (K01, 4.51/h) signifies that CRM-LF ensured rapid absorption of the CRM into the central compartment. This was followed by the distribution of CRM from the central to peripheral compartment (K12, 2.69/h). The rate of CRM transfer from the peripheral to central compartment (K21, 0.15/h) was slow. This encourages higher tissue levels of CRM as compared with plasma levels. The study provides an explanation of the therapeutic efficacy of CRM, despite very low/undetectable levels in the plasma. View Full-Text
Keywords: curcumin; bioavailability; absorption; pharmacokinetic modeling curcumin; bioavailability; absorption; pharmacokinetic modeling
Show Figures

Figure 1

MDPI and ACS Style

Pawar, Y.B.; Munjal, B.; Arora, S.; Karwa, M.; Kohli, G.; Paliwal, J.K.; Bansal, A.K. Bioavailability of a Lipidic Formulation of Curcumin in Healthy Human Volunteers. Pharmaceutics 2012, 4, 517-530.

AMA Style

Pawar YB, Munjal B, Arora S, Karwa M, Kohli G, Paliwal JK, Bansal AK. Bioavailability of a Lipidic Formulation of Curcumin in Healthy Human Volunteers. Pharmaceutics. 2012; 4(4):517-530.

Chicago/Turabian Style

Pawar, Yogesh B., Bhushan Munjal, Saurabh Arora, Manoj Karwa, Gunjan Kohli, Jyoti K. Paliwal, and Arvind K. Bansal. 2012. "Bioavailability of a Lipidic Formulation of Curcumin in Healthy Human Volunteers" Pharmaceutics 4, no. 4: 517-530.

Find Other Styles

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Back to TopTop